Rajesh Rajan, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 100 Jackson Pike, Gallipolis, OH 45631 Phone: 855-446-5937 Fax: 740-446-5982 |
Beenu Singh, MBBS Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 100 Jackson Pike, Holzer Clinic Llc, Gallipolis, OH 45631 Phone: 718-918-5640 Fax: 718-918-7460 |
News Archive
There might be a simpler and less expensive method of controlling the progression of HIV, according to several preliminary studies presented last Thursday at the XVI International AIDS Conference in Toronto, the Los Angeles Times reports (Chong, Los Angeles Times, 8/18).
Quickly detecting and identifying dangerous biotoxins is now a reality, thanks to the xMAP Biothreat Toxin Panel (BTP) by Luminex. The xMAP Biothreat Toxin Panel is the first multiplex assay to rapidly detect and identify the six most easily acquired and most dangerous biotoxins. All six of these biotoxins are on the US government's list of most dangerous substances.
Inspire Medical Systems, a leading developer of neuro-stimulation therapies for the treatment of obstructive sleep apnea (OSA), announced today that the company has received approval from the U.S. Food and Drug Administration (FDA) to begin its STAR pivotal clinical trial. The STAR trial (Stimulation Therapy for Apnea Reduction), is a multi-center study that will evaluate both the safety and effectiveness of Inspire Upper Airway Stimulation (UAS) therapy in patients with moderate to severe obstructive sleep apnea (OSA).
Much remains unknown about diseases and the way our bodies respond to them, in part because the human genome is the complete DNA assembly that makes each person unique. A Virginia Tech professor and his team of researchers have created new technology to help in understanding how the human body battles diseases.
The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) today voted 12 yes, 4 no, and 1 abstention that AstraZeneca has established sufficient benefit to offset the observed risks to support the use of CRESTOR®
› Verified 8 days ago